Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients

Ophélie Fourdinier, Eva Schepers, Valérie Metzinger-Le Meuth, Griet Glorieux, Sophie Liabeuf, Francis Verbeke, Raymond Vanholder, Benjamin Brigant, Anneleen Pletinck, Momar Diouf, Stéphane Burtey, Gabriel Choukroun, Ziad A. Massy, Laurent Metzinger* (Corresponding Author), Angel Argiles, Joachim Beige, Philippe Brunet, Gerald Cohen, Omar Abou Deif, Pieter EvenepoelDanilo Fliser, Ivo Fridolin, Andreas Gmerek, Joachim Jankowski, Vera Jankowski, Roos Masereeuw, Harald Mischak, Alberto Ortiz, Alessandra Perna, Juan Mariano Rodriguez-Portillo, Joost Schanstra, Goce Spasovski, Dimitrios Stamatialis, Sonja Steppan, Markus Storr, Bernd G. Stegmayr, Peter Stenvinkel, Paul J. Thornalley, Andrej Wiecek, on behalf of the European Uremic Toxin Work Group-EUTox

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

51 Citations (Scopus)
115 Downloads (Pure)


Several microRNAs (miRNAs) have been linked to chronic kidney disease (CKD) mortality, cardiovascular (CV) complications and kidney disease progression. However, their association with clinical outcomes remains poorly evaluated. We used real-time qPCR to measure serum levels of miR-126 and miR-223 in a large cohort of 601 CKD patients (CKD stage G1 to G5 patients or on renal replacement therapy – CKD G5D) from Ghent University Hospital and 31 healthy controls. All-cause mortality and cardiovascular and renal events were registered as endpoints over a 6 year follow-up period. miR-126 levels were significantly lower from CKD stage G2 on, compared to controls. The serum levels of miR-223 were significantly lower from CKD stage G3B on. When considering overall mortality, patients with levels of either miR-126 or miR-223 below the median had a lower survival rate. Similar results were observed for CV and renal events. The observed link between the two miRNAs’ seric levels and mortality, cardiovascular events or renal events in CKD appears to depend on eGFR. However, this does not preclude their potential role in the pathophysiology of CKD. In conclusion, CKD is associated with a decrease in circulating miR-223 and miR-126 levels.

Original languageEnglish
Article number4477
JournalScientific reports
Issue number1
Publication statusPublished - 14 Mar 2019


Dive into the research topics of 'Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients'. Together they form a unique fingerprint.

Cite this